Ndhlovu, L. C., Umaki, T., Chew, G. M., Chow, D. C., Agsalda, M., Kallianpur, K. J., . . . Shikuma, C. M. (2014). Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: Implications for HIV-associated neurocognitive disease (HAND). J Neurovirol.
シカゴスタイル引用形Ndhlovu, Lishomwa C., et al. "Treatment Intensification With Maraviroc (CCR5 Antagonist) Leads to Declines in CD16-expressing Monocytes in CART-suppressed Chronic HIV-infected Subjects and Is Associated With Improvements in Neurocognitive Test Performance: Implications for HIV-associated Neurocognitive Disease (HAND)." J Neurovirol 2014.
MLA引用形式Ndhlovu, Lishomwa C., et al. "Treatment Intensification With Maraviroc (CCR5 Antagonist) Leads to Declines in CD16-expressing Monocytes in CART-suppressed Chronic HIV-infected Subjects and Is Associated With Improvements in Neurocognitive Test Performance: Implications for HIV-associated Neurocognitive Disease (HAND)." J Neurovirol 2014.